CrossRef
Works that cite this article, indexed by Crossref.
Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: A systematic review and meta-analysis
American Journal of Health-System Pharmacy 78(24) (2021)
Lorenzo Villa-Zapata; Briggs S Carhart; John R Horn; Philip D Hansten; Vignesh Subbian; Sheila Gephart; Malinda Tan; Andrew Romero; Daniel C Malone
Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity
Frontiers in Physiology 12 (2022)
Aneesh Dhore-patil; Tariq Thannoun; Rohan Samson; Thierry H. Le Jemtel
Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
Journal of Diabetes Investigation 8(4) (2017)
Li‐Jing Sun; Yan‐Ni Sun; Jian‐Ping Shan; Geng‐Ru Jiang
Efficacy and safety of dual vs single renin–angiotensin–aldosterone system blockade in chronic kidney disease
Medicine 100(35) (2021)
Mingming Zhao; Hua Qu; Rumeng Wang; Yi Yu; Meiying Chang; Sijia Ma; Hanwen Zhang; Yuejun Wang; Yu Zhang
Reporting Quality Assessment of Randomized Controlled Trials Published in Nephrology Urology Monthly Journal
Nephro-Urology Monthly 7(4) (2015)
Alireza Mehrazmay; Alireza Karambakhsh; Mahmood Salesi
Efficacy and Safety of Dual Blockade of the Renin–Angiotensin–Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis
American Journal of Cardiovascular Drugs 19(3) (2019)
Yanhuan Feng; Rongshuang Huang; Janet Kavanagh; Lingzhi Li; Xiaoxi Zeng; Yi Li; Ping Fu
The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy
Current Clinical Pharmacology 14(2) (2019)
Luxitaa Goenka; Raghavan Padmanaban; Melvin George
Research Progress of Mineralocorticoid Receptor Antagonists on Diabetic Kidney Disease
Advances in Clinical Medicine 13(01) (2023)
璇 王
Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy
Journal of Diabetes Research 2015 (2015)
Songyan Wang; Bing Li; Chunguang Li; Wenpeng Cui; Lining Miao
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Pharmaceuticals 14(6) (2021)
Nina Vodošek Hojs; Sebastjan Bevc; Robert Ekart; Nejc Piko; Tadej Petreski; Radovan Hojs
Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease
Drug Delivery 30(1) (2023)
Xian Chen; Wenni Dai; Hao Li; Zhe Yan; Zhiwen Liu; Liyu He
Development, optimization, and assessment of losartan nano-bilosomes to mitigate diabetes-induced microvascular complications in Sprague Dawley rats
Journal of Drug Delivery Science and Technology 92 (2024)
Mona Qushawy; Ghareb M. Soliman; Yasmin Mortagi; Mohamed El-Sherbiny; Nehal Elsherbiny
Captopril and Spironolactone can Attenuate Diabetic Nephropathy in Wistar Rats by Targeting ABCA1 and microRNA-33
Current Pharmaceutical Design 28(16) (2022)
Tina Ghaffari; Nariman Moradi; Elham Chamani; Zahra Ebadi; Reza Fadaei; Shahin Alizadeh-Fanalou; Sahar Yarahmadi; Soudabeh Fallah
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Frontiers in Pharmacology 12 (2021)
Daiji Kawanami; Yuichi Takashi; Yoshimi Muta; Naoki Oda; Dai Nagata; Hiroyuki Takahashi; Makito Tanabe
Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes
International Urology and Nephrology 51(4) (2019)
Dan Dong; Ting-ting Fan; Ying-shi Ji; Jin-yu Yu; Shan Wu; Li Zhang
Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population
BMC Research Notes 9(1) (2016)
Romance Nguetse Djoumessi; Jean Jacques N. Noubiap; Francois Folefack Kaze; Mickael Essouma; Alain Patrick Menanga; Andre Pascal Kengne; Jean Claude Mbanya; Eugene Sobngwi
Organoprotective Effects of Spironolactone on Top of Ramipril Therapy in a Mouse Model for Alport Syndrome
Journal of Clinical Medicine 10(13) (2021)
Diana Rubel; Yanqin Zhang; Nenja Sowa; Rainer Girgert; Oliver Gross